{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T07:04:33Z","timestamp":1789628673434,"version":"build-2803163510"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T00:00:00Z","timestamp":1717459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T00:00:00Z","timestamp":1717459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>A series of consensus guidelines on medical treatment of acromegaly have been produced in the last two decades. However, little information is available on their application in clinical practice. Furthermore, international standards of acromegaly care have not been published. The aim of our study was to report current standards of care for medical therapy of acromegaly, using results collected through an audit performed to validate criteria for definition of Pituitary Tumor Centers of Excellence (PTCOE).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Details of medical treatment approaches to acromegaly were voluntarily provided by nine renowned international centers that participated in this audit. For the period 2018\u20132020, we assessed overall number of acromegaly patients under medical treatment, distribution of patients on different treatment modalities, overall biochemical control rate with medical therapy, and specific control rates for different medical treatment options.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Median number of total patients and median number of new patients with acromegaly managed annually in the endocrinology units of the centers were 206 and 16.3, respectively. Median percentage of acromegaly patients on medical treatment was 48.9%. Among the patients on medical treatment, first-generation somatostatin receptor ligand (SRL) monotherapy was used with a median rate of 48.7%, followed by combination therapies with a median rate of 29.3%. Cabergoline monotherapy was used in 6.9% of patients. Pegvisomant monotherapy was used in 7 centers and pasireotide monotherapy in 5 centers, with median rates of 7.9% and 6.3%, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Current standards of care in PTCOEs include use of first-generation SRLs as the first medical option in about 50% of patients, as recommended by consensus guidelines. However, some patients are kept on this treatment despite inadequate control suggesting that cost-effectiveness, availability, patient preference, side effects, and therapeutic inertia may play a possible role also in PTCOE. Moreover, at odds with consensus guidelines, other monotherapies for acromegaly appear to have a marginal role as compared to combination therapies as extrapolated from PTCOE practice data. Presence of uncontrolled patients in each treatment category suggest that further optimization of medical therapy, as well as use of other therapeutic tools such as radiosurgery may be needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11102-024-01397-w","type":"journal-article","created":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T03:05:31Z","timestamp":1717470331000},"page":"381-388","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Standards of care for medical management of acromegaly in pituitary tumor centers of excellence (PTCOE)"],"prefix":"10.1007","volume":"27","author":[{"given":"Andrea","family":"Giustina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. M.","family":"Uygur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Frara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Barkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. R.","family":"Biermasz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Chanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Freda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gadelha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Haberbosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U. B.","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Lamberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Laws","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. B.","family":"Nachtigall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Popovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Reincke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. J.","family":"van der Lely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. A. H.","family":"Wass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Melmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. F.","family":"Casanueva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,4]]},"reference":[{"issue":"1","key":"1397_CR1","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41572-019-0071-6","volume":"5","author":"A Colao","year":"2019","unstructured":"Colao A, Grasso LFS, Giustina A, Melmed S, Chanson P, Pereira AM et al (2019) Acromegaly Nat Rev Dis Primers 5(1):20","journal-title":"Acromegaly Nat Rev Dis Primers"},{"issue":"6","key":"1397_CR2","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1210\/endrev\/bnac010","volume":"43","author":"S Melmed","year":"2022","unstructured":"Melmed S, Kaiser UB, Lopes MB, Bertherat J, Syro LV, Raverot G et al (2022) Clinical Biology of the Pituitary Adenoma. Endocr Rev 43(6):1003\u20131037","journal-title":"Endocr Rev"},{"issue":"15","key":"1397_CR3","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/S0002-9149(99)80721-8","volume":"75","author":"A Giustina","year":"1995","unstructured":"Giustina A, Boni E, Romanelli G, Grassi V, Giustina G (1995) Cardiopulmonary performance during exercise in acromegaly, and the effects of acute suppression of growth hormone hypersecretion with octreotide. Am J Cardiol 75(15):1042\u20131047","journal-title":"Am J Cardiol"},{"issue":"6","key":"1397_CR4","doi-asserted-by":"publisher","first-page":"655","DOI":"10.3803\/EnM.2023.601","volume":"38","author":"A Giustina","year":"2023","unstructured":"Giustina A (2023) Acromegaly and bone: an update. Endocrinol Metab (Seoul) 38(6):655\u2013666","journal-title":"Endocrinol Metab (Seoul)"},{"key":"1397_CR5","doi-asserted-by":"crossref","unstructured":"Giustina A, Barkan A, Beckers A, Biermasz N, Biller BMK, Boguszewski C et al (2020) A Consensus on the diagnosis and treatment of Acromegaly comorbidities: an update. J Clin Endocrinol Metab. 105(4)","DOI":"10.1210\/clinem\/dgz096"},{"issue":"8","key":"1397_CR6","first-page":"450","volume":"107","author":"A Giustina","year":"2016","unstructured":"Giustina A (2016) [Acromegaly: reducing diagnostic delay]. Recenti Prog Med 107(8):450\u2013451","journal-title":"Recenti Prog Med"},{"issue":"6","key":"1397_CR7","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1530\/EJE-20-0019","volume":"182","author":"D Esposito","year":"2020","unstructured":"Esposito D, Ragnarsson O, Johannsson G, Olsson DS (2020) Prolonged diagnostic delay in acromegaly is associated with increased morbidity and mortality. Eur J Endocrinol 182(6):523\u2013531","journal-title":"Eur J Endocrinol"},{"key":"1397_CR8","doi-asserted-by":"crossref","unstructured":"Chiloiro S, Giampietro A, Gagliardi I, Bondanelli M, Veleno M, Ambrosio MR et al (2022) Impact of the diagnostic delay of acromegaly on bone health: data from a real life and long term follow-up experience. Pituitary 1\u201311","DOI":"10.1007\/s11102-022-01266-4"},{"issue":"1","key":"1397_CR9","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1210\/er.2018-00115","volume":"40","author":"MR Gadelha","year":"2019","unstructured":"Gadelha MR, Kasuki L, Lim DST, Fleseriu M (2019) Systemic complications of Acromegaly and the impact of the Current Treatment Landscape: an update. Endocr Rev 40(1):268\u2013332","journal-title":"Endocr Rev"},{"issue":"4","key":"1397_CR10","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s11154-020-09588-z","volume":"21","author":"A Giustina","year":"2020","unstructured":"Giustina A, Barkhoudarian G, Beckers A, Ben-Shlomo A, Biermasz N, Biller B et al (2020) Multidisciplinary management of acromegaly: a consensus. Rev Endocr Metab Disord 21(4):667\u2013678","journal-title":"Rev Endocr Metab Disord"},{"key":"1397_CR11","doi-asserted-by":"crossref","unstructured":"Giustina A, Biermasz N, Casanueva FF, Fleseriu M, Mortini P, Strasburger C, et al (2024) Consensus on criteria for acromegaly diagnosis and remission. Pituitary 27(1):7\u201322","DOI":"10.1007\/s11102-023-01373-w"},{"issue":"9","key":"1397_CR12","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","volume":"14","author":"S Melmed","year":"2018","unstructured":"Melmed S, Bronstein MD, Chanson P, Klibanski A, Casanueva FF, Wass JAH et al (2018) A Consensus Statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol 14(9):552\u2013561","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"1397_CR13","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1210\/jc.2014-4113","volume":"100","author":"S Melmed","year":"2015","unstructured":"Melmed S, Popovic V, Bidlingmaier M, Mercado M, van der Lely AJ, Biermasz N et al (2015) Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial. J Clin Endocrinol Metab 100(4):1699\u20131708","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1397_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11102-020-01091-7","volume":"24","author":"M Fleseriu","year":"2021","unstructured":"Fleseriu M, Biller BMK, Freda PU, Gadelha MR, Giustina A, Katznelson L et al (2021) A Pituitary Society update to acromegaly management guidelines. Pituitary 24(1):1\u201313","journal-title":"Pituitary"},{"issue":"Suppl 1","key":"1397_CR15","doi-asserted-by":"publisher","first-page":"S140","DOI":"10.2337\/dc23-S009","volume":"46","author":"NA ElSayed","year":"2023","unstructured":"ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D et al (2023) 9. Pharmacologic approaches to Glycemic Treatment: standards of Care in Diabetes-2023. Diabetes Care 46(Suppl 1):S140\u2013s57","journal-title":"Diabetes Care"},{"issue":"5","key":"1397_CR16","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s11102-017-0838-2","volume":"20","author":"FF Casanueva","year":"2017","unstructured":"Casanueva FF, Barkan AL, Buchfelder M, Klibanski A, Laws ER, Loeffler JS et al (2017) Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): a Pituitary Society statement. Pituitary 20(5):489\u2013498","journal-title":"Pituitary"},{"issue":"3","key":"1397_CR17","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.ecl.2020.05.010","volume":"49","author":"S Frara","year":"2020","unstructured":"Frara S, Rodriguez-Carnero G, Formenti AM, Martinez-Olmos MA, Giustina A, Casanueva FF (2020) Pituitary Tumors Centers of Excellence. Endocrinol Metab Clin North Am 49(3):553\u2013564","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"5","key":"1397_CR18","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s11102-023-01345-0","volume":"26","author":"A Giustina","year":"2023","unstructured":"Giustina A, Uygur MM, Frara S, Barkan A, Biermasz NR, Chanson P et al (2023) Pilot study to define criteria for Pituitary Tumors Centers of Excellence (PTCOE): results of an audit of leading international centers. Pituitary 26(5):583\u2013596","journal-title":"Pituitary"},{"issue":"17","key":"1397_CR19","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1517\/14656566.2013.847090","volume":"14","author":"A Giustina","year":"2013","unstructured":"Giustina A, Karamouzis I, Patelli I, Mazziotti G (2013) Octreotide for acromegaly treatment: a reappraisal. Expert Opin Pharmacother 14(17):2433\u20132447","journal-title":"Expert Opin Pharmacother"},{"key":"1397_CR20","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/bs.pmbts.2015.10.015","volume":"138","author":"S Frara","year":"2016","unstructured":"Frara S, Maffezzoni F, Mazziotti G, Giustina A (2016) The Modern Criteria for Medical Management of Acromegaly. Prog Mol Biol Transl Sci 138:63\u201383","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"2","key":"1397_CR21","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s12020-014-0206-1","volume":"46","author":"M Marazuela","year":"2014","unstructured":"Marazuela M, Ramos-Lev\u00ed A, Sampedro-N\u00fa\u00f1ez M, Bernabeu I (2014) Cabergoline treatment in acromegaly: pros. Endocrine 46(2):215\u2013219","journal-title":"Endocrine"},{"issue":"6","key":"1397_CR22","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s40618-017-0614-1","volume":"40","author":"A Giustina","year":"2017","unstructured":"Giustina A, Arnaldi G, Bogazzi F, Cannav\u00f2 S, Colao A, De Marinis L et al (2017) Pegvisomant in acromegaly: an update. J Endocrinol Invest 40(6):577\u2013589","journal-title":"J Endocrinol Invest"},{"issue":"11","key":"1397_CR23","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S2213-8587(14)70169-X","volume":"2","author":"MR Gadelha","year":"2014","unstructured":"Gadelha MR, Bronstein MD, Brue T, Coculescu M, Fleseriu M, Guitelman M et al (2014) Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol 2(11):875\u2013884","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"1397_CR24","doi-asserted-by":"publisher","first-page":"D17","DOI":"10.1530\/EJE-19-0998","volume":"182","author":"AJ van der Lely","year":"2020","unstructured":"van der Lely AJ, Kuhn E, Muhammad A, Coopmans EC, Neggers SJ, Chanson P (2020) Pegvisomant and not somatostatin receptor ligands (SRLs) is first-line medical therapy for acromegaly. Eur J Endocrinol 182(6):D17\u2013d29","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"1397_CR25","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s12020-023-03317-7","volume":"80","author":"A Giustina","year":"2023","unstructured":"Giustina A, di Filippo L, Uygur MM, Frara S (2023) Modern approach to resistant acromegaly. Endocrine 80(2):303\u2013307","journal-title":"Endocrine"},{"key":"1397_CR26","doi-asserted-by":"crossref","unstructured":"Urwyler SA, Samperi I, Lithgow K, Mavilakandy A, Matheou M, Bradley K et al (2024) Efficacy of cabergoline in non-irradiated patients with acromegaly: a multi-centre cohort study. Eur J Endocrinol","DOI":"10.1093\/ejendo\/lvae003"},{"issue":"7","key":"1397_CR27","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.tem.2016.04.014","volume":"27","author":"S Frara","year":"2016","unstructured":"Frara S, Maffezzoni F, Mazziotti G, Giustina A (2016) Current and emerging aspects of diabetes Mellitus in Acromegaly. Trends Endocrinol Metab 27(7):470\u2013483","journal-title":"Trends Endocrinol Metab"},{"issue":"3","key":"1397_CR28","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1007\/s12020-021-02711-3","volume":"73","author":"S Chiloiro","year":"2021","unstructured":"Chiloiro S, Giampietro A, Visconti F, Rossi L, Donfrancesco F, Fleseriu CM et al (2021) Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus Pegvisomant. Endocrine 73(3):658\u2013666","journal-title":"Endocrine"},{"issue":"6","key":"1397_CR29","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1530\/EJE-18-0616","volume":"179","author":"M Buchfelder","year":"2018","unstructured":"Buchfelder M, van der Lely AJ, Biller BMK, Webb SM, Brue T, Strasburger CJ et al (2018) Long-term treatment with pegvisomant: observations from 2090 acromegaly patients in ACROSTUDY. Eur J Endocrinol 179(6):419\u2013427","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"1397_CR30","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1530\/EJE-21-0239","volume":"185","author":"M Fleseriu","year":"2021","unstructured":"Fleseriu M, F\u00fchrer-Sakel D, van der Lely AJ, De Marinis L, Brue T, van der Lans-Bussemaker J et al (2021) More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY. Eur J Endocrinol 185(4):525\u2013538","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"1397_CR31","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s11102-010-0269-9","volume":"14","author":"A Giustina","year":"2011","unstructured":"Giustina A, Bronstein MD, Casanueva FF, Chanson P, Ghigo E, Ho KK et al (2011) Current management practices for acromegaly: an international survey. Pituitary 14(2):125\u2013133","journal-title":"Pituitary"},{"key":"1397_CR32","doi-asserted-by":"crossref","unstructured":"Bonert V, Mirocha J, Carmichael J, Yuen KCJ, Araki T, Melmed S (2020) Cost-effectiveness and efficacy of a Novel Combination Regimen in Acromegaly: a prospective, randomized trial. J Clin Endocrinol Metab. 105(9)","DOI":"10.1210\/clinem\/dgaa444"},{"issue":"5","key":"1397_CR33","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1210\/jc.2013-3757","volume":"99","author":"JD Carmichael","year":"2014","unstructured":"Carmichael JD, Bonert VS, Nu\u00f1o M, Ly D, Melmed S (2014) Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis. J Clin Endocrinol Metab 99(5):1825\u20131833","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1397_CR34","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s11102-015-0684-z","volume":"19","author":"A Colao","year":"2016","unstructured":"Colao A, Auriemma RS, Pivonello R, Kasuki L, Gadelha MR (2016) Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly. Pituitary 19(3):235\u2013247","journal-title":"Pituitary"},{"issue":"7","key":"1397_CR35","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1210\/jc.2017-00142","volume":"102","author":"A Giustina","year":"2017","unstructured":"Giustina A, Mazziotti G, Cannav\u00f2 S, Castello R, Arnaldi G, Bugari G et al (2017) High-dose and High-Frequency Lanreotide Autogel in Acromegaly: a Randomized, Multicenter Study. J Clin Endocrinol Metab 102(7):2454\u20132464","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1397_CR36","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1530\/EJE-09-0372","volume":"161","author":"A Giustina","year":"2009","unstructured":"Giustina A, Bonadonna S, Bugari G, Colao A, Cozzi R, Cannavo S et al (2009) High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial. Eur J Endocrinol 161(2):331\u2013338","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"1397_CR37","first-page":"3555","volume":"106","author":"A Giustina","year":"2021","unstructured":"Giustina A, Bronstein MD, Chanson P, Petersenn S, Casanueva FF, Sert C et al (2021) International Multicenter Validation Study of the SAGIT\u00ae Instrument in Acromegaly. J Clin Endocrinol Metab 106(12):3555\u20133568","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"1397_CR38","doi-asserted-by":"publisher","first-page":"A355","DOI":"10.1016\/j.jval.2014.08.754","volume":"17","author":"A Giustina","year":"2014","unstructured":"Giustina A, Bevan J, Bronstein M, Casanueva F, Chanson P, Petersenn S et al (2014) Sagit\u00a9: a novel clinician-reported outcome for managing Acromegaly in Clinical Practice. Value Health 17(7):A355","journal-title":"Value Health"},{"issue":"11","key":"1397_CR39","doi-asserted-by":"publisher","first-page":"5478","DOI":"10.1210\/jc.2019-00825","volume":"104","author":"S Chiloiro","year":"2019","unstructured":"Chiloiro S, Bima C, Tartaglione T, Giampietro A, Gessi M, Lauretti L et al (2019) Pasireotide and Pegvisomant Combination Treatment in Acromegaly resistant to second-line therapies: a longitudinal study. J Clin Endocrinol Metab 104(11):5478\u20135482","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"1397_CR40","doi-asserted-by":"publisher","first-page":"3644","DOI":"10.1210\/jc.2014-2032","volume":"99","author":"SJ Neggers","year":"2014","unstructured":"Neggers SJ, Franck SE, de Rooij FW, Dallenga AH, Poublon RM, Feelders RA et al (2014) Long-term efficacy and safety of pegvisomant in combination with long-acting somatostatin analogs in acromegaly. J Clin Endocrinol Metab 99(10):3644\u20133652","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1397_CR41","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/j.1365-2265.2009.03620.x","volume":"71","author":"PJ Trainer","year":"2009","unstructured":"Trainer PJ, Ezzat S, D\u2019Souza GA, Layton G, Strasburger CJ (2009) A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly. Clin Endocrinol (Oxf) 71(4):549\u2013557","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"1397_CR42","doi-asserted-by":"publisher","first-page":"e532","DOI":"10.1210\/clinem\/dgz187","volume":"105","author":"A Ghajar","year":"2020","unstructured":"Ghajar A, Jones PS, Guarda FJ, Faje A, Tritos NA, Miller KK et al (2020) Biochemical control in Acromegaly with Multimodality therapies: outcomes from a Pituitary Center and Changes over Time. J Clin Endocrinol Metab 105(3):e532\u2013e543","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1397_CR43","doi-asserted-by":"publisher","first-page":"e36411","DOI":"10.1371\/journal.pone.0036411","volume":"7","author":"A Giustina","year":"2012","unstructured":"Giustina A, Mazziotti G, Torri V, Spinello M, Floriani I, Melmed S (2012) Meta-analysis on the effects of octreotide on tumor mass in acromegaly. PLoS ONE 7(5):e36411","journal-title":"PLoS ONE"},{"issue":"1","key":"1397_CR44","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s11102-009-0169-z","volume":"13","author":"G Mazziotti","year":"2010","unstructured":"Mazziotti G, Giustina A (2010) Effects of lanreotide SR and autogel on tumor mass in patients with acromegaly: a systematic review. Pituitary 13(1):60\u201367","journal-title":"Pituitary"},{"issue":"5","key":"1397_CR45","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1210\/jc.2008-2332","volume":"94","author":"G Mazziotti","year":"2009","unstructured":"Mazziotti G, Floriani I, Bonadonna S, Torri V, Chanson P, Giustina A (2009) Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. J Clin Endocrinol Metab 94(5):1500\u20131508","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1397_CR46","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1530\/EJE-10-0811","volume":"164","author":"G Mazziotti","year":"2011","unstructured":"Mazziotti G, Porcelli T, Bogazzi F, Bugari G, Cannav\u00f2 S, Colao A et al (2011) Effects of high-dose octreotide LAR on glucose metabolism in patients with acromegaly inadequately controlled by conventional somatostatin analog therapy. Eur J Endocrinol 164(3):341\u2013347","journal-title":"Eur J Endocrinol"},{"issue":"9471","key":"1397_CR47","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1016\/S0140-6736(05)63011-5","volume":"365","author":"J Feenstra","year":"2005","unstructured":"Feenstra J, de Herder WW, ten Have SM, van den Beld AW, Feelders RA, Janssen JA et al (2005) Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 365(9471):1644\u20131646","journal-title":"Lancet"},{"issue":"1","key":"1397_CR48","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s11102-016-0737-y","volume":"20","author":"DS Lim","year":"2017","unstructured":"Lim DS, Fleseriu M (2017) The role of combination medical therapy in the treatment of acromegaly. Pituitary 20(1):136\u2013148","journal-title":"Pituitary"},{"issue":"3","key":"1397_CR49","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.eprac.2021.12.017","volume":"28","author":"DST Lim","year":"2022","unstructured":"Lim DST, Fleseriu M (2022) Personalized Medical treatment of patients with acromegaly: a review. Endocr Pract 28(3):321\u2013332","journal-title":"Endocr Pract"},{"issue":"12","key":"1397_CR50","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1080\/14656566.2016.1199687","volume":"17","author":"F Maffezzoni","year":"2016","unstructured":"Maffezzoni F, Formenti AM, Mazziotti G, Frara S, Giustina A (2016) Current and future medical treatments for patients with acromegaly. Expert Opin Pharmacother 17(12):1631\u20131642","journal-title":"Expert Opin Pharmacother"},{"issue":"5","key":"1397_CR51","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1007\/s11102-022-01264-6","volume":"25","author":"M Couselo","year":"2022","unstructured":"Couselo M, Frara S, Giustina A, Casanueva FF (2022) Pituitary tumor centers of excellence for Cushing\u2019s disease. Pituitary 25(5):772\u2013775","journal-title":"Pituitary"},{"key":"1397_CR52","doi-asserted-by":"crossref","unstructured":"Romero-Gameros CA, Gonz\u00e1lez-Virla B, Vargas-Ortega G, Sosa-Eroza E, Rend\u00f3n-Mac\u00edas ME, Balc\u00e1zar-Hern\u00e1ndez LJ et al (2023) Efficiency and safety of CyberKnife Robotic Radiosurgery in the Multimodal Management of patients with Acromegaly. Cancers (Basel). 15(5)","DOI":"10.3390\/cancers15051438"},{"key":"1397_CR53","doi-asserted-by":"publisher","unstructured":"Gola M, Bonadonna S, Mazziotti G, Amato G, Giustina A (2006) Resistance to somatostatin analogs in acromegaly: an evolving concept?. J Endocrinol Invest 29(1):86\u201393. https:\/\/doi.org\/10.1007\/BF03349183","DOI":"10.1007\/BF03349183"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-024-01397-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-024-01397-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-024-01397-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T09:18:06Z","timestamp":1722331086000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-024-01397-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,4]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["1397"],"URL":"https:\/\/doi.org\/10.1007\/s11102-024-01397-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4094890\/v1","asserted-by":"object"}]},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,4]]},"assertion":[{"value":"26 April 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A. Giustina is a Consultant for Ipsen, Pfizer, and Recordati, and received Research Grants to Institutions from, Pfizer. M.M. Uygur received a Grant from Pfizer. S. Frara received consultancy and speaker fees from Ipsen, Pfizer, Novartis, and Recordati. A.J. van der Lely received consultancy and\/ or speakers\u2019 fees from Amoly Pharma SA, Dexel, Cambian, Crinetics, Ipsen, and Pfizer. S. Melmed is a Consultant for Ionis, Ipsen, and Novo Nordisk and receives a Research Grant from Recordati. Other authors do not declare any competing interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}